跳至主要内容
临床试验/CTRI/2020/07/026793
CTRI/2020/07/026793已完成2 期

Prospective, parallel arm, randomized controlled trial to evaluate safety and efficacy of Panchgavya Therapy in prophylaxis and as an adjuvant therapy in management of Covid 19. - Nil

Ionisation Filtration Industries PvtLtd0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients with RT-PCR confirmed COVID-19 illness.
  • Age of 18-65 years of either sex (Both including)
  • Mild to Moderate Covid 19 disease (NEWS score NMT 7)
  • Signed informed consent.
  • Cases with or without presenting with fever and/or upper respiratory tract illness (Influenza-like illness, ILI).
  • Subjects at high risk of exposure to COVID 19
  • Health care and frontline workers involved in the treatment of COVID19 cases
  • Family members of COVID19 cases or direct contact

排除标准

  • Subjects with any comorbidity which is critical at the screening
  • Allergies, known to be allergic to research drugs
  • Confirmed pneumonia cases with or without symptoms
  • Patients who have participated in other clinical trials within 1 month
  • Proves unfit for the study as a sole discretion of the investigator
  • Being pregnant or breastfeeding
  • Requiring ICU admission at the screening
  • Past History of MI, Epileptic episodes
  • Not giving consent

研究者

发起方
Ionisation Filtration Industries PvtLtd

相似试验